The Biologics License Application for Sirukumab, submitted by Johnson & Johnson's Janssen Biotech subsidiary, is scheduled to be reviewed by a panel of outside experts convened by the FDA on August 2, 2017.Sirukumab, whose proposed trade name is Plivensia, is being co-developed by Janssen Biotech and GlaxoSmithKline for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have failed or are intolerant to one or more disease modifying anti-rheumatic drugs.The FDA usually follows the panels' recommendation, although it is not required to do so. We estimate that the decision is likely to be announced by September 23, 2017.If approved, Sirukumab will compete with Roche’s Actemra and Sanofi/ Regeneron's Kevzara. While all the three – Sirukumab, Actemra and Kevzara – need to be administered as injections, they differ in their dosing frequency. Actemra is administered once a week, Kevzara is administered once every two weeks while Sirukumab is a once-monthly injection.GSK closed Friday's trading at $40.93, up 0.44%.